More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$9.48B
EPS
0.66
P/E ratio
20.2
Price to sales
10.6
Dividend yield
--
Beta
1.88814
Previous close
$62.76
Today's open
$62.42
Day's range
$61.50 - $63.57
52 week range
$26.76 - $68.03
show more
CEO
Michael S. Weiss
Employees
399
Headquarters
Morrisville, NC
Exchange
NASDAQ Capital Market
Shares outstanding
151147827
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™
NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 5 on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 32nd year.The Company's growth between fiscal years 2022 to 2025 was fueled by BRIUMVI® revenues, which was approved to treat adult individuals with relapsing forms of multiple sclerosis in December of 2022.
Business Wire • 9 hours ago

3 Stocks Rallying After Strong Q3 Earnings and Raised Guidance
The Q3 earnings season has delivered several big winners, with Hasbro (HAS), IDEXX Laboratories (IDXX), and TG Therapeutics (TGTX) all posting strong results that have helped drive relative strength over the last month, with each raising also guidance in one way or another.
Zacks Investment Research • a day ago

TG Therapeutics: 3 Key Takeaways for Long-Term Investors
TG Therapeutics raised full-year 2026 global revenue guidance to $1 billion. Subcutaneous BRIUMVI could more than double peak sales opportunity.
The Motley Fool • Nov 15, 2026

TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up
TG Therapeutics beats Q3 earnings and revenue estimates as Briumvi demand accelerates, shares rise 5.9%, and 2026 revenue guidance climbs to $1 billion.
Zacks Investment Research • Nov 10, 2026

4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.
Zacks Investment Research • Nov 10, 2026

What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call
TG Therapeutics NASDAQ: TGTX raised its 2026 revenue outlook after third-quarter sales of its multiple sclerosis treatment BRIUMVI climbed 52% in the United States, and executives said they expect a stronger fourth quarter.
MarketBeat • Nov 9, 2026

TG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call Transcript
TG Therapeutics, Inc. ( TGTX ) Q3 2026 Earnings Call November 9, 2026 8:30 AM EST Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, CEO & President Adam Waldman - Chief Commercialization Officer Sean Power - CFO, Corporate Secretary & Treasurer Conference Call Participants Michael DiFiore - Evercore ISI Institutional Equities, Research Division Tara Bancroft - TD Cowen, Research Division Jiale Song - Jefferies LLC, Research Division William Wood - B. Riley Securities, Inc., Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Operator Greetings, and welcome to the TG Therapeutics Third Quarter 2026 Conference Call.
Seeking Alpha • Nov 9, 2026

TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four ye.
Business Wire • Nov 9, 2026

TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $2.43 per share a year ago.
Zacks Investment Research • Nov 9, 2026

TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Nov 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell TG Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.